Nod for 鈥榤ix and match鈥 booster shots
Print Edition
The US Food and Drug Administration on Wednesday authorized using a so-called 鈥渕ix and match鈥 strategy for people who require a booster shot of a COVID-19 vaccine after their primary series.
鈥淭he FDA has determined that the known and potential benefits of the use of a single heterologous booster dose outweigh the known and potential risks of their use in eligible populations,鈥 the agency said in a statement.
The Pfizer, Moderna, and Johnson & Johnson vaccines are authorized in the United States. A single dose of any of them may now be used following completion of primary vaccination with a different COVID-19 vaccine.
According to the new decision, people who received two Moderna shots initially and are 65 years or older, over 18 years and at high risk for COVID-19, or over 18 and have high occupational exposure, may now receive a booster.
All adults who received the one-shot J&J vaccine more than two months ago are also eligible for a booster.
Previously, only immune compromised people or people who belonged to elderly or high risk groups and had received the Pfizer vaccine initially were eligible for a boost.
The data supporting the decisions come from research reviewed by the FDA.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
